InvestSMART

Conneqt Health Limited (ASX:CQT)

ALERT: Price-sensitive ASX Announcement for CQT
Current share price for CQT : $0.024 -0.01 (-29.41%)+
Announcement
Release
28 Oct 2025 8:58AM
Price at Release
$0.034
Full Release
download
Summary
Conneqt Health Limited, trading as ASX: CQT, announced the award of a new Phase 2b clinical trial contract with a U.S.-based biopharmaceutical company to develop therapies for hypertension and cardiovascular diseases. The trial, expected to commence in Q4 2025, will last approximately nine months at 30 sites across the U.S. Conneqt will provide 30 SphygmoCor® XCEL systems and 60 Oscar 2 ABPM systems, along with setup, training, and data management services. The contract is valued at approximately A$1.1 million (US$716,000). This agreement underscores Conneqt's technology capabilities in delivering precise and scalable solutions for cardiovascular studies.
Key Points
  • Awarded Phase 2b clinical trial contract with a U.S.-based company.
  • Focus on therapies for hypertension and cardiovascular diseases.
  • Trial commences in Q4 2025 across 30 U.S. sites.
  • Contract valued at approximately A$1.1 million.
  • Provision of SphygmoCor® XCEL and Oscar 2 ABPM systems.
  • Includes setup, training, and data management services.
  • Highlights Conneqt's precision and scalability in cardiovascular studies.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.